CIBC Private Wealth Group LLC Acquires New Position in Certara, Inc. (NASDAQ:CERT)

CIBC Private Wealth Group LLC bought a new position in shares of Certara, Inc. (NASDAQ:CERT) in the fourth quarter, HoldingsChannel reports. The firm bought 206,717 shares of the company’s stock, valued at approximately $2,278,000.

Other hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC grew its stake in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares during the period. Blue Trust Inc. grew its position in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Certara by 204.7% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock worth $58,000 after purchasing an additional 3,656 shares during the last quarter. KBC Group NV raised its position in shares of Certara by 64.1% during the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after purchasing an additional 3,125 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Up 3.6 %

Shares of CERT stock opened at $10.23 on Thursday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.18. The firm’s 50 day moving average price is $12.29 and its two-hundred day moving average price is $11.43. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -51.15, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60.

Analysts Set New Price Targets

Several research firms have issued reports on CERT. Barclays raised their price target on shares of Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. William Blair restated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Stephens reiterated an “overweight” rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen began coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Certara has an average rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.